Page last updated: 2024-08-23

etoposide and Familial Waldenstrom's Macroglobulinaemia

etoposide has been researched along with Familial Waldenstrom's Macroglobulinaemia in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's4 (57.14)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
D'Sa, S; Dorman, J; Marzolini, MA; Thomson, KJ1
Al-Katib, AM; Mensah-Osman, EJ; Mohammad, RM; Osman, NI; Wu, HY1
Alinari, L; Baccarani, M; Stefoni, V; Tani, M; Zinzani, PL1
Al-Katib, AM; Mensah-Osman, EJ; Mohammad, RM1
Lapeyre-Mestre, M; Montastruc, JL; Pathak, A; Rigal-Huguet, F; Tournamille, JF1
Ezoe, A; Kohda, K; Kuga, T; Matsumoto, S; Mochizuki, C; Nakazawa, O; Niitsu, Y; Nobuoka, A; Watanabe, N1
Bessho, M; Fukuda, M; Hirashima, K; Horibe, T; Itoh, K; Kawai, N; Murohashi, I; Sakata, T; Shimada, T; Takeuchi, H1

Trials

1 trial(s) available for etoposide and Familial Waldenstrom's Macroglobulinaemia

ArticleYear
[Utility of daily oral administration of etoposide in 25 cases of refractory hematological malignancies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:3

    Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Stomatitis; Survival Analysis; Vomiting; Waldenstrom Macroglobulinemia

1997

Other Studies

6 other study(ies) available for etoposide and Familial Waldenstrom's Macroglobulinaemia

ArticleYear
BEAM-conditioned autologous SCT improves the quality of response in Waldenström's macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre's 10-year experience.
    Bone marrow transplantation, 2014, Volume: 49, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Humans; Lymphoma; Male; Melphalan; Middle Aged; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Waldenstrom Macroglobulinemia

2014
2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:14

    Topics: Antigens, Neoplasm; Blotting, Western; Culture Media, Serum-Free; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Microscopy, Confocal; Microscopy, Fluorescence; Neoplasm Transplantation; Protein Isoforms; Quinoxalines; Time Factors; Tumor Cells, Cultured; Up-Regulation; Waldenstrom Macroglobulinemia

2002
Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
    Leukemia research, 2003, Volume: 27, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case Management; Chlorambucil; Cladribine; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Immunoglobulin M; Male; Middle Aged; Mitoxantrone; Plasmapheresis; Prednisone; Rituximab; Severity of Illness Index; Thalidomide; Vidarabine; Vinblastine; Vincristine; Vinorelbine; Waldenstrom Macroglobulinemia

2003
Preclinical evaluation of 2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid as a modulator of etoposide in human Waldenstrom's macroglobulinemia xenograft model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Nov-15, Volume: 9, Issue:15

    Topics: Animals; Cell Division; Etoposide; Humans; Mice; Mice, SCID; Quinoxalines; Transplantation, Heterologous; Waldenstrom Macroglobulinemia

2003
[Cardiac effects of cytokines produced after rituximab infusion].
    Bulletin du cancer, 2005, Volume: 92, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathy, Dilated; Drug Monitoring; Etoposide; Fatal Outcome; Humans; Ifosfamide; Immunoglobulin M; Male; Methotrexate; Middle Aged; Mitoguazone; Rituximab; Waldenstrom Macroglobulinemia

2005
[Waldenström's macroglobulinemia effectively treated with chronic daily oral administration of low-dose etoposide].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:13

    Topics: Administration, Oral; Aged; Drug Administration Schedule; Etoposide; Female; Humans; Lymph Nodes; Nucleic Acid Synthesis Inhibitors; Waldenstrom Macroglobulinemia

1998